Hepatocyte growth factor (HGF) plays a plethora of roles in cancer metastasis and tumour growth. The interaction between tumour cells and their surrounding stromal environment is a crucial factor regulating tumour invasion and metastasis. Stromal fibroblasts are the main source of HGF in the body, and release HGF as an inactive precursor (pro‐HGF). HGF activator (HGFA), matriptase, urokinase‐type plasminogen activator and hepsin are the main factors responsible for converting pro‐HGF into active HGF. HAI‐1 and HAI‐2 are 2 novel Kunitz‐type serine protease inhibitors that regulate HGF activity through inhibition of HGFA, matriptase and hepsin action. Recent studies demonstrate that HAI‐1 and HAI‐2 may also potently inhibit a number of other pro‐metastatic serine proteases and therefore have direct bearing on the spread of tumours. Our study examined the potential of these HAI's to suppress the influence of HGF and regulate cancer metastasis. We generated a retroviral expression system that induced HAI expression in a human fibroblast cell line. Forced expression of either HAI‐1 or HAI‐2 in these fibroblasts resulted in a dramatic decrease in the production of bioactive hepatocyte growth factor (HGF). This reduction in HGF activity subsequently suppressed HGF's metastatic influence on breast cancer cells. To further assess the anti‐cancer properties of HAI‐1 and HAI‐2 we generated recombinant HAI proteins. These recombinant HAI proteins possessed the ability to potently quench HGF activity. We also demonstrate that these recombinant HAI's suppressed fibroblast‐mediated breast cancer invasion. An additional ribozyme transgenes study revealed that elimination of HAI‐1 and HAI‐2 expression, in an MDA‐MB‐231 breast cancer cell line, significantly enhanced the migratory, proliferative and invasive nature of these breast cancer cells. Overall, our data demonstrates the important roles of HAI‐1 and HAI‐2 in cancer metastasis, and reveals that these serine protease inhibitors display strong therapeutic potential. © 2006 Wiley‐Liss, Inc.